Related Experiment Video
Updated: Jun 24, 2025
09:45
Photodynamic Therapy with Blended Conducting Polymer/Fullerene Nanoparticle Photosensitizers
Published on: October 28, 2015
8.5K
A GSH-Responsive Prodrug with Simultaneous Triple-Activation Capacity for Photodynamic/Sonodynamic Combination
Caiting Deng1,2, Jingjing Zhang2, Fanchun Hu2
1Institute of Medical Engineering, School of Basic Medical Science, Health Science Center, Xi'an Jiaotong University, No. 76 Yanta West Road, Xi'an, Shaanxi, 710061, China.
Small (Weinheim an Der Bergstrasse, Germany)
|June 5, 2024
Summary
A novel dual-activatable prodrug, pro-THPC, enables precise combination cancer therapy using photodynamic and sonodynamic approaches. This approach minimizes side effects by targeting tumors effectively, offering a promising new treatment strategy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cancer Therapy
Background:
- Photodynamic therapy (PDT) and sonodynamic therapy (SDT) are emerging cancer treatment modalities.
- Current limitations include off-target toxicity and limited penetration depth.
- Development of targeted and activatable therapeutic agents is crucial.
Purpose of the Study:
- To design and synthesize a dual-sensitizer prodrug, pro-THPC, for combined PDT and SDT.
- To formulate pro-THPC into nanoparticles (NPs) for enhanced in vivo delivery and reduced skin phototoxicity.
- To evaluate the therapeutic efficacy and tumor-targeting capabilities of pro-THPC NPs in vivo.
Main Methods:
- Synthesis of the dual-sensitizer prodrug pro-THPC.
- Formulation of pro-THPC into nanoparticles (NPs).
- In vivo fluorescence imaging to assess tumor accumulation and targeting.
- Evaluation of reactive oxygen species (ROS) generation and therapeutic efficacy in tumor models.
Main Results:
- Pro-THPC NPs demonstrated significantly higher tumor-to-normal tissue ratios compared to control groups.
- Glutathione (GSH) activation of pro-THPC NPs led to localized ROS generation within tumors.
- Combined PDT and SDT using pro-THPC NPs effectively eradicated tumors with reduced skin phototoxicity.
- In vivo studies confirmed enhanced tumor targeting and therapeutic outcomes.
Conclusions:
- Pro-THPC NPs represent a novel strategy for precise antitumor combination therapy.
- The GSH-activated dual-sensitizer approach offers improved tumor specificity and minimized off-target effects.
- This nanotechnology-based platform holds significant potential for advanced cancer treatment.
